Comparative proteomic profiles of meningioma subtypes.

@article{Okamoto2006ComparativePP,
  title={Comparative proteomic profiles of meningioma subtypes.},
  author={Hiroaki Okamoto and J. Li and Alexander O. Vortmeyer and Howard. Jaffe and Youn‐Soo Lee and Sven Gl{\"a}sker and Tae Sung Sohn and Weifen F Zeng and Barbara L. Ikejiri and Martin A. Proescholdt and Christina Mayer and Robert J. Weil and Edward H. Oldfield and Zhengping Zhuang},
  journal={Cancer research},
  year={2006},
  volume={66 20},
  pages={
          10199-204
        }
}
Meningiomas are classified into three groups (benign, atypical, and anaplastic) based on morphologic characteristics. Atypical meningiomas, which are WHO grade 2 tumors, and anaplastic meningiomas, which are WHO grade 3 tumors, exhibit an increased risk of recurrence and premature death compared with benign WHO grade 1 tumors. Although atypical and anaplastic meningiomas account for <10% of all of meningiomas, it can be difficult to distinguish them from benign meningiomas by morphologic… 
View on PubMed
cancerres.aacrjournals.org
45 Citations
Highly Influential Citations
2
Background Citations
7
Methods Citations
5
Results Citations
2

45 Citations

Citation Type

Citation Type

Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype
TLDR
Analysis of the protein spectra in benign meningiomas could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial mening iomas of grade I.
Quantitative Proteomic Analysis of Meningiomas for the Identification of Surrogate Protein Markers
TLDR
A comprehensive serum proteomic analysis of different grades of meningiomas is reported by using multiple quantitative proteomic and immunoassay-based approaches to obtain mechanistic insights about disease pathogenesis and identify grade specific protein signatures.
Proteomic data in meningiomas: post-proteomic analysis can reveal novel pathophysiological pathways
TLDR
Systematic review of shotgun proteomics and network analysis provides insight into meningioma pathophysiology despite the many barriers and difficulties that are inherent to this type of study.
Comprehensive overview of extracellular vesicle proteomics in meningioma: future strategy
TLDR
The utility of proper knowledge of extracellular vesicle proteins and their profiles in different grades can help in better understanding of pathogenesis, diagnosis, prognosis and treatment of meningioma.
Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation
TLDR
A meningioma-specific protein signature in blood circulation of mening ioma patients is identified and highlights the importance of equilibrium between tumor-promoting factors and anti-tumor immunity.
Proteomics pinpoints alterations in grade I meningiomas of male versus female patients
TLDR
Shooting shotgun proteomics was used to compare the proteomic profile of grade I meningioma biopsies of male and female patients and identified enriched pathways for cell-matrix organization and for females, pathways related to RNA transporting and processing.
Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.
TLDR
The role of nine proteins, particularly related to tumorigenesis and grading of meningiomas, and their associated pathways could be considered possible diagnostic, prognostic biomarkers, and eventually therapeutic targets are highlighted.
Unbiased global proteomic profiling of patient-derived meningiomas of all grades to identify molecular signatures of differentially expressed proteins and phosphoproteins.
TLDR
A comparative mass spectrometry analysis of meningioma tissue of all WHO grades, analysing global proteins, phosphoproteins and phosphopeptides identified proteins involved in their pathogenesis and grade-specific candidates relevant for tumour progression.
Meningioma Tumors: Detection of Subgroups
TLDR
This review summarizes the most recent advances in the detection of meningioma subgroups using traditional and modern high throughput molecular techniques and suggests that there are at least two molecular subgroups of histological benignMeningiomas.
Anaplastic meningioma: Progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence
TLDR
It is proposed that grading of meningiomas as outlined by WHO is of more critical prognostic import than histologic sub‐typing, and must include a thorough survey of the tumor‐brain interface.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Microarray‐based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression
TLDR
Investigation of potential correlations between microarray expression data and genomic aberrations, detected by comparative genomic hybridization (CGH), demonstrated that losses on chromosomes 10 and 14 were associated with distinct expression profiles, including increased expression of several genes related to the insulin‐like growth factor or wingless pathways.
Protein patterns and proteins that identify subtypes of glioblastoma multiforme
TLDR
It is demonstrated that specific proteomic patterns can be reproducibly identified by two-dimensional gel electrophoresis from limited numbers of selectively procured, microdissected tumor cells and that two patterns of GBMs, primary versus secondary, previously distinguished by clinical and genetic differences, can be recognized at the protein level.
Molecular pathogenesis of meningiomas
TLDR
A better understanding of the molecular mechanisms involved in meningioma pathogenesis may not only lead to the identification of novel diagnostic and prognostic marker but will also facilitate the development of new pathogenesis-based therapeutic strategies.
SPARC: a potential diagnostic marker of invasive meningiomas.
  • S. Rempel, S. Ge, J. Gutiérrez
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
TLDR
SPARC, a secreted, extracellular matrix-associated protein implicated in the modulation of cell adhesion and migration, was evaluated as a potential diagnostic marker of invasive meningiomas and is capable of distinguishing the histomorphologically benign noninvasive from the histomorphicologically benign but invasive meniomas, in the absence of the infiltrative interface.
Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis
TLDR
Proteome analysis is useful to develop a novel system for the prediction of biological aggressiveness of gliomas and the proteins identified here could be novel biomarkers for survival prediction and rational targets for antiglioma therapy.
Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression.
TLDR
A model for the genomic alterations associated with meningioma progression is proposed on the basis of the most common aberrations identified in the various malignancy grades.
Expression of epithelial and extracellular matrix protein markers in meningiomas
TLDR
Cells from the primary cultures revealed a fine skeleton of intercellular matrix proteins stainable by immunohistochemical methods, providing further proof that meningioma cells possess the capability to elaborate extracellular matrix proteins, a major mesenchymal function akin to that of fibroblasts.
Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings.
TLDR
Tumors that present with complex genetic alterations, even those with a benign histological grade, are potentially aggressive and require closer follow up and the FISH method appears to be more accurate than the standard cytogenetic one in detecting these alterations.
Diagnosis and Treatment of Atypical and Anaplastic Meningiomas: A Review
TLDR
The current literature is reviewed and available information is integrated and summarized to determine a logical approach to atypical and anaplastic meningiomas.
Atypical and malignant meningiomas: a clinicopathological review.
TLDR
Of the 25 patients treated at Henry Ford Hospital between 1976 and 1990, 11 (44%) died during follow-up: 2 in the perioperative period, 8 within the first 5 years, and 1 died 11 years after the diagnosis.
...
1
2
3
4
5
...